DDInter704 DDInter785
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018]
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Isradipine
Isradipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Tofacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Everolimus {u} (Compound) upregulates {v} (Gene) KLHL21
KLHL21 {u} (Gene) is upregulated by {v} (Compound) Isradipine
Isradipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isradipine
Isradipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Everolimus {u} (Compound) downregulates {v} (Gene) RBM34
RBM34 {u} (Gene) is downregulated by {v} (Compound) Isradipine
Isradipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Everolimus {u} (Compound) causes {v} (Side Effect) Malnutrition
Malnutrition {u} (Side Effect) is caused by {v} (Compound) Isradipine
Isradipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Rifabutin
Rifabutin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paclitaxel
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Everolimus {u} (Compound) downregulates {v} (Gene) RBM34
RBM34 {u} (Gene) is upregulated by {v} (Compound) Irinotecan
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Everolimus (Compound) upregulates KLHL21 (Gene) and KLHL21 (Gene) is upregulated by Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Everolimus (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) is downregulated by Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Everolimus (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Rifabutin and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Everolimus (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) is upregulated by Irinotecan (Compound) and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib